Device Impact on the Efficacy of Serum Product Study
The goal of this clinical trial is to learn whether combining a beauty device with the test product affects skin parameters in women troubled by wrinkles. It aims to evaluate the impact of the beauty device on the efficacy of the test product. The main questions it aims to answer are:
- Does the combination of the beauty device plus test product achieve better skin improvement compared with using the test product alone?
Researchers will compare beauty device + test product applied to one half of the face and one side of the neck against the test product alone applied to the contralateral half-face and neck, to see whether the beauty device enhances the efficacy of the test product.
Participants will:
- Receive randomized split-face and split-neck treatment during the study
- Attend 10 scheduled study visits
- Undergo standardized image capture, clinical assessment and instrumental skin measurement
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Yanwen Jiang
- Numéro de téléphone: +86 13501700841
- E-mail: jiangyanwen@china-norm.com
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine
- Recrutement
- Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
-
Contact:
- Yanwen Jiang
- Numéro de téléphone: +86 13501700841
- E-mail: jiangyanwen@china-norm.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 1. Chinese female with 25 - 55 years old.
- 2. All skin types, 50% self-declare sensitive skin.
- 3. Self- declare with concerns on facial wrinkle problems.
- 4. The difference in clinical grading between the two sides of the face should be less than one point.
- 5. Presenting with following certain degree skin qualities clinical grading by dermatologist: Skin radiance, brightness, global appearance of fine lines, elasticity, plumpness, skin firmness: 3≤grade≤6 (refer to 0-9 scale); Crow's feet wrinkles: 2≤ grade (Skin Aging Atlas); Underneath eye wrinkle: 2≤ grade (Skin Aging Atlas); Nasolabial folds:2 ≤ grade (Skin Aging Atlas); Ptosis of the lower part of the face 1≤grade (Skin Aging Atlas);
- 6. Did not participate any clinical test or cosmetic product test on skin within 3 months.
- 7. Did not participate any chemical/beauty procedures for previous 6 months.
- 8. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
- 9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
- 10. Must be willing to comply with all study protocol requirements.
Exclusion Criteria:
- 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
- 2. Subject deprived of rights by a court or administrative order.
- 3. Major subject to a guardianship order.
- 4. Subject residing in a health or social care establishment.
- 5. Patient in an emergency setting.
- 6. Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
- 7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
- 8. Immuno-compromised subject.
- 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
- 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
- 11. Subject regularly practicing aquatic or nautical sports.
- 12. Subject regularly attending a sauna.
- 13. Subject with physical highly sensitive constitution.
- 14. Subject with cardiovascular or circulatory history.
- 15. Subject with a history of skin cancer or malignant melanoma.
- 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune- suppressants in the last 6 months before study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Arm 1
Randomly assigned half-face and half-neck receives the beauty device combined with the test product. The study includes short-term on-site application and long-term home-use regimen. |
Short-term: 1.48 g test product applied on half-face & half-neck, massaged by beauty device for about 5 min 50 sec at study site. Long-term: Subjects follow standardized home skincare routine between visits. On-site visits: treatment side receives beauty device and test product. |
|
Comparateur actif: Arm 2
Contralateral half-face and half-neck receives only the test product without the beauty device, as within-subject control. The same home skincare regimen is followed. |
Short-term: 0.45 g test product manually applied on half-face by staff, no beauty device. Long-term: same full-face home skincare routine. On-site visits: only test product is applied on this control side without beauty device treatment. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dermatologist clinical assessment of skin parameters using modified Griffiths 10-point scale
Délai: 2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.
|
A dermatologist evaluates skin parameters on the left and right half-face/half-neck separately. Assessments include skin tone, skin quality and wrinkle parameters graded on a 0-9 scale. Half-point (0.5) or incremental values (0.4/0.6) may be used. The rater is blinded to prior scores after baseline. |
2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Stratum corneum hydration measured by Corneometer® CM 825
Délai: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
|
Skin hydration is measured bilaterally on cheeks using Corneometer® CM 825 (capacitance method). The mean value of 3 consecutive valid readings is recorded; higher values indicate greater hydration. |
Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
|
|
Transepidermal water loss (TEWL) measured by Vapometer
Délai: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
|
TEWL is measured bilaterally on cheeks using Vapometer. One reading is taken per site. Unit: g/m²h; lower values indicate better skin barrier function. |
Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
|
|
wrinkle analysis using Antera 3D
Délai: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
|
Antera 3D generates 3D colour images of skin surface by analysing shadow and light reflection. Standard wrinkle photographs are captured and analysed. |
Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
|
|
Skin texture analysis using VisioScan VC20
Délai: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4
|
VisioScan VC20 (UV CCD imaging probe) captures skin images on bilateral cheeks and neck. Images are processed and analysed by SELS software to evaluate skin smoothness. |
Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
3D facial imaging using Vectera-H2
Délai: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
|
Handheld Vectera-H2 captures 180° stereophotogrammetric 3D facial images. Assessment endpoint: facial fullness. |
Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
|
|
Facial imaging acquisition using VISIA®-CR (Canfield)
Délai: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4
|
Facial images are captured by trained staff with VISIA®-CR, equipped with multiple light sources (standard, cross-polarized, parallel polarized, oblique, UV). Images are taken from left, central and right views with subject wearing hairnet and eyes closed. |
Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- C26005101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .